

# Carboplatin versus etoposide/cisplatin for advanced metastatic seminoma

<b>Submission date</b> 28/02/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 11/09/2007	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Miss Sharon Naylor

**Contact details**  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
TE12

## Study information

**Scientific Title**

**Study objectives**

Compare the efficacy of carboplatin with a combination of etoposide and cisplatin in the treatment of advanced metastatic seminoma.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Not Specified

**Participant information sheet****Health condition(s) or problem(s) studied**

Cancer

**Interventions**

Arm 1 - 4 cycles of carboplatin.

Arm 2 - 4 cycles of cisplatin/etoposide.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Carboplatin versus Etoposide / Cisplatin

**Primary outcome measure**

Progression-free survival

**Secondary outcome measures**

Response, survival, toxicity.

**Overall study start date**

01/08/1990

**Completion date**

31/12/1995

## Eligibility

**Key inclusion criteria**

Histologically verified testicular/extra-gonadal pure seminoma

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

112

**Key exclusion criteria**

Previous chemotherapy.

**Date of first enrolment**

01/08/1990

**Date of final enrolment**

31/12/1995

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

## Sponsor information

**Organisation**

Medical Research Council (MRC) (UK)

**Sponsor details**

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

**Sponsor type**

Research council

**Website**

<http://www.mrc.ac.uk>

**Funder(s)****Funder type**

Research council

**Funder Name**

Medical Research Council (UK)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

# Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	01/12/2000		Yes	No